Cellectis (CLLS)
(Delayed Data from NSDQ)
$3.02 USD
+0.07 (2.37%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $3.02 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLLS 3.02 +0.07(2.37%)
Will CLLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLLS
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't?
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLLS
Here are the major earnings after the close Monday
Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result
Cellectis GAAP EPS of -$0.24 misses by $0.03, revenue of $16M beats by $4.36M
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates | CLLS Stock News
Earnings Scheduled For August 4, 2025